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Abstract
Clofazimine has shown activity against Mycobacterium tuberculosis, including multidrug-resistant strains in vitro and in animal studies. How-
ever, clinical experience with clofazimine in multidrug-resistant tuberculosis (MDR-TB) is scarce. We reported our clinical experience
with 39 MDR-TB patients treated with combination regimens that included clofazimine. From January 2008 to March 2011, 39 patients
received clofazimine for the treatment of MDR-TB in Shanghai Pulmonary Hospital. Patients had isolates resistant to a median of six
drugs (range, 2–11 drugs). Of the 39 cases, 36 had cavitary changes noted on initial chest radiograph or chest computed tomography,
and positive sputum-smear microscopy results at the time of MDR-TB diagnosis. At data censure, 15 of the 39 patients had successful
therapy, with at least ﬁve consistently negative cultures documented for the ﬁnal 12 months of treatment. Eleven continued to receive
treatment. There were no deaths. Thirteen patients had a poor outcome, including four defaults and nine treatment failures. Culture
conversion occurred in 22 cases at a median of 12 weeks. Side-effects occurred in 34 patients, mainly including skin discolouration, ich-
thyosis and gastrointestinal adverse events. No patients reported signiﬁcant toxicity likely to be attributable to clofazimine therapy.
Adverse events were managed by combinations of dose adjustment and symptom management. In our experience, clofazimine was well
tolerated and may have efﬁcacy in the treatment of MDR-TB.
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Introduction
Tuberculosis (TB) is still a global health problem with nine
million new cases and almost two million deaths per year
[1]. Most patients with TB can be successfully treated using
short-course medical chemotherapy [2]. However, tubercu-
losis treatment is challenged by increasing multidrug-resistant
TB (MDR-TB) and extensively drug-resistant TB (XDR-TB)
[3–5]. Further, second-line drugs used for treating TB are
usually characterized by lower efﬁcacy or greater toxicity.
The increased incidence of MDR-TB has created an urgent
necessity for the new effective anti-tuberculosis drugs and
for alternative therapy regimens.
Clofazimine was developed initially by Barry et al. [6] to
be used speciﬁcally for the treatment of tuberculosis. How-
ever, it showed less activity against tuberculosis in an animal
model. Subsequently, on the basis of the fact that it concen-
trates extensively inside macrophages and on the basis of the
logic of using an intracellular drug on an intracellular parasite,
clofazimine has been used successfully for the treatment of
leprosy [7]. As more serious tuberculosis caused by MDR
strains has emerged, researchers have sought to reestablish
the chemotherapeutic roles of clofazimine. Some studies
showed that clofazimine had good activity against drug-resis-
tant strains of Mycobacterium tuberculosis, both in vitro and in
animal studies [7,8]. The most important feature with regard
to the activity of clofazimine was that none of the Mycobacte-
rium tuberculosis strains, including the MDR strains, showed
resistance to the drug in vitro, and the chemotherapeutic
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activity of clofazimine was comparable to that of isoniazid
and rifampin in the mouse model [7,8].
Recent case series have reported improvement among
patients with MDR-TB whose treatment regimens included
clofazimine [9–13]. However, published clinical experience
with clofazimine and MDR-TB has generally been limited by
small sample sizes. Further, limited information was reported
regarding treatment outcomes and adverse events among
Chinese patients with MDR-TB treated with a clofazimine-
containing regimen. We examined treatment outcomes, as
well as adverse events, among a cohort of 39 MDR-TB
patients, including 19 patients with XDR-TB, who were trea-
ted with clofazimine as part of salvage regimens in Shanghai
Pulmonary Hospital, China.
Methods
Study design
We retrospectively reviewed records of MDR-TB patients
who received treatment with clofazimine for ‡1 month in
Shanghai Pulmonary Hospital between January 2008 and
March 2011. All patients received clofazimine as part of an
expanded tuberculosis treatment regimen, tailored to the
susceptibility results of each isolate and given by directly
observed therapy (DOT) throughout treatment. Treatment
regimens included clofazimine and ‡4 companion drugs
selected according to individual drug history and recent sus-
ceptibility results. At the time of treatment initiation, clofazi-
mine was administered orally at a dosage of 100 mg daily to
all patients. Patients were monitored weekly for sputum cul-
ture status and occurrence of adverse events.
Drug susceptibility testing (DST) was conducted at the
central laboratory of Shanghai Pulmonary Hospital. DST was
performed using the BACTEC MGIT 960 (Becton Dickinson
Microbiology Systems, Sparks, MD, USA) and the agar pro-
portions method for ﬁrst- and second-line drugs (isoniazid,
rifampicin, ethambutol, streptomycin, amikacin, capreomycin,
para-aminosalicylic acid, protionamide, rifapentine, pasiniazide
and oﬂoxacin).
We used a standardized data abstraction form to obtain
information from Shanghai Pulmonary Hospital TB registry
and medical record library, including: demographics and co-
morbid conditions; clinical, radiographic and microbiological
characteristics; serial sputum testing and culture results; sur-
gical intervention for TB; treatment regimens, durations, and
outcomes; and occurrence and management of adverse
events.
We examined treatment outcomes by clinical and radio-
graphic improvement and by sputum smear and culture con-
version. We examined adverse events by reviewing weekly
biochemistry data and weekly inquiries regarding skin pig-
mentation, ichthyosis, gastrointestinal reaction and so on.
Because this study used routinely collected surveillance and
treatment data without patient identiﬁers, institutional
review board approval was not required.
Deﬁnitions
Standard treatment outcome deﬁnitions were as proposed
by Laserson et al. [14]. A patient who completed treatment
and was consistently culture negative with at least ﬁve
results for the ﬁnal 12 months of treatment was deﬁned as
cured. Treatment failure was deﬁned as two or more posi-
tive cultures in the last 12 months of treatment, or if a medi-
cal decision was made to terminate treatment due to poor
response or adverse events. Sputum conversion was deﬁned
as two consecutive negative sputum smears in patients who
were smear positive at diagnosis. Time to culture conversion
was deﬁned as time from treatment start to date of the ﬁrst
of two consecutive negative cultures.
Statistical analysis
We carried out a univariate analysis to show differences
between patients with treatment success and failure in our
study. We reported statistical signiﬁcance using the v2 test
for categorical variables and the Student’s t-test for continu-
ous variables. A p <0.05 was considered signiﬁcant. Analysis
was carried out with Stata version 9.0 (Stata Corporation,
College Station, TX, USA).
Results
Patient characteristics and disease status
More than 100 patients were treated for culture-conﬁrmed
MDR-TB in Shanghai Pulmonary Hospital from January 2008
to March 2011. Thirty-nine MDR-TB patients, including 19
with XDR-TB, received clofazimine as part of individualized
treatment regimens (Table 1). All patients treated with clof-
azimine were domestic born, and sex distribution (ten
females and 29 males) was not equal. At the time of MDR-
TB treatment initiation, the mean patient age was 38 (range,
20–54 years). Eleven patients had at least one co-morbid
condition; none had human immunodeﬁciency virus co-infec-
tion. No patient had surgical interventions to treat TB.
Shanghai Pulmonary Hospital clinicians provided TB care for
all patients. All patients were hospitalized or were on DOT
for the whole duration of MDR-TB treatment.
Of the 39 patients with pulmonary tuberculosis, all had a
history of previous treatment for tuberculosis. Thirty-six had
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TABLE 2. Treatment outcomes and toxicities
Patient
Time from start of
MDR-TB treatment
to culture conversion
(weeks) Reported toxicity
Reduced
CFZ dose
Duration
of reduction
(months)
Discontinue
CFZ
Treatment
outcome
1 8 Skin discolouration 100 mg, qod 12 Yes Cure
2 8 Skin discolouration, ichthyosis,
nausea
100 mg, qod 12 Yes Cure
3 12 Skin discolouration 100 mg, qod 9 Yes Cure
4 24 Skin discolouration, ichthyosis 100 mg, qod 13 Yes Cure
5 Positive Skin discolouration, ichthyosis No No Yes Default, lost
6 48 Skin discolouration, nausea,
vomiting
100 mg, qod 13 No (treatment with
antiemetic)
Continued
treatment
7 Positive Skin discolouration, ichthyosis No No Yes Failure
8 Positive Skin discolouration, ichthyosis,
dizziness
No No Yes Failure
9 4 Skin discolouration, nausea,
vomiting
No No No (treatment with
antiemetic)
Continued
treatment
10 Positive Skin discolouration, ichthyosis 100 mg, qod 10 Yes Failure
11 Positive Skin discolouration, ichthyosis 100 mg, qod 13 Yes Failure
12 8 Skin discolouration, nausea 100 mg, qod 12 Yes (treatment with
antiemetic)
Cure
13 40 Skin discolouration 100 mg, qod 12 No Continued
treatment
14 Positive Skin discolouration, nausea,
vomiting
100 mg, qod 11 Yes (treatment with
antiemetic)
Failure
15 4 Skin discolouration, ichthyosis,
nausea, vomiting
No No Yes Cure
16 12 Skin discolouration No No No Continued
treatment
17 Positive Skin discolouration, nausea,
vomiting
No No Yes Failure
18 24 Skin discolouration, nausea 100 mg, qod 12 Yes Cure
19 Positive Skin discolouration 100 mg, qod 12 Yes Failure
20 12 Skin discolouration, ichthyosis 100 mg, qod 12 Yes Cure
21 24 Skin discolouration 100 mg, qod 12 Yes Cure
22 8 Skin discolouration, nausea,
vomiting, anaemia, leucopenia
No No No (treatment with
antiemetic)
Continued
treatment
23 2 Skin discolouration, nausea,
vomiting, anaemia, peripheral
neuropathy, rash
No No No (treatment with
erythropoietin, ferrous
sulphate, blood
transfusion,
and anti-allergic drugs)
Continued
treatment
24 4 Skin discolouration, nausea,
vomiting, anaemia, leucopenia,
thrombocytopenia, peripheral
neuropathy, rash
No No Yes (treatment with
erythropoietin, ferrous
sulphate, G-CSF,
antiemetic,
and anti-allergic drugs)
Cure
25 Positive None No No No Continued
treatment
26 2 Nausea, vomiting No No No (treatment with
antiemetic)
Cure
27 Positive Skin discolouration, ichthyosis No No Yes (treatment with
anti-allergic drugs)
Default, lost
28 4 None No No No Cure
29 2 Skin discolouration, nausea,
vomiting
100 mg, qod 9 No Cure
30 4 None No No No Continued
treatment
31 Positive Skin discolouration, No No No Continued
treatment
32 Positive None No No Yes Default, lost
33 Positive Skin discolouration, ichthyosis,
nausea, vomiting
No No No (treatment with
anti-allergic drugs
and antiemetic)
Continued
treatment
34 Positive Nausea, vomiting, insomnia,
depression
No No Yes Failure
35 Positive Skin discolouration No No No Continued
treatment
36 Positive Nausea, vomiting No No Yes (treatment with
antiemetic)
Default, lost
37 8 Skin discolouration, leukopenia No No No Cure
38 Positive Skin discolouration, nausea,
vomiting
100 mg, qod 17 Yes Failure
39 8 None No No No Cure
MDR-TB, multidrug-resistant tuberculosis; CFZ, clofazimine.
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cavitary changes noted on initial chest radiograph or chest
computed tomography, and had positive sputum-smear
microscopy results at the time of MDR-TB diagnosis. All
patients had positive cultures; the DST results are shown in
Table 1.
Initiation and duration of clofazimine use
Patients’ Mycobacterium tuberculosis isolates were resistant to
a median of six drugs (range, 2–11) and they were treated for
TB for a median of 38 months (range, 1–183) prior to starting
clofazimine (Table 1). Indications for using clofazimine were
failure of previous MDR-TB treatment regimen in 19 patients,
relapse in seven patients, and inability to tolerate other sec-
ond-line drugs in ﬁve patients. The other eight patients did
not report detailed sputum culture results in their previous
medical record. The mean duration of clofazimine administra-
tion was 13 months (range, 2–25) (Table 1). Clofazimine was
added to regimens containing a median of six other drugs
(range, 4–7), including a ﬂuoroquinolone (n = 37, 95%), pyraz-
inamide (n = 30, 77%), protionamide (n = 28, 72%), pasiniaz-
ide (n = 21, 54%), isoniazid (n = 18, 46%), para-aminosalicylic
acid (n = 17, 44%), clarithromycin (n = 16, 41%), amikacin
(n = 12, 31%), capreomycin (n = 10, 26%), rifabutin (n = 7,
18%), linezolid (n = 3, 13%), amoxicillin/clavulanate (n = 5,
13%), rifapentine (n = 4, 10%) and azithromycin (n = 2, 5%).
Treatment outcomes
Table 2 shows treatment outcomes and toxicities. Fifteen
(38%) of the 39 patients had successful therapy, with at least
ﬁve consistently negative cultures documented for the ﬁnal
12 months of treatment. Of the 15 successful patients, seven
(47%) had XDR-TB; the remaining eight (53%) had MDR-TB.
Eleven patients (28%) were still receiving treatment. Thirteen
patients (33%) had an unsatisfactory outcome. Of the 13
patients, nine (23%) had treatment failure, and four (10%)
refused to continue treatment and were lost after a median
of 9 months (range, 2–13) of therapy. Most patients with
unsatisfactory outcome discontinued treatment because of
economic reasons, adverse effects and/or poor response.
They all remained culture-positive for Mycobacterium tubercu-
losis during treatment. Only three patients showed clinical
and/or radiographic improvement. There was no death.
Of the nine failed patients, six (67%) had XDR-TB and
three (33%) had MDR-TB at the start of treatment. More
XDR-TB cases were found in patients with treatment failure
as compared with patients with successful treatment.
Patients with failed treatment had isolates resistant to more
of the 11 agents for which DST testing was routinely per-
formed, and had longer time for TB therapy prior to starting
clofazimine than that of patients with successful treatment,
but the difference did not reach statistical signiﬁcance
(6.4 ± 2.2 vs. 5.0 ± 1.4, p 0.06; 46.8 months ± 50.6 vs.
31.7 months ± 46.8, p 0.46). Whereas patients with success-
ful treatment used more drugs in clofazimine-containing regi-
mens than patients with treatment failure, the difference was
signiﬁcant (6.9 ± 0.6 vs. 6.1 ± 1.1, p <0.05).
For the 39 patients, 22 achieved conversion of culture to
negative. The median time to culture conversion was
12 weeks after the initiation of MDR-TB therapy (range, 2–
48 weeks). Among the 22 patients, seven showed culture
conversion, but not ﬁve times. So we could not deﬁne these
cases as treatment success.
Of the 15 patients who were successfully cured, ten have
not relapsed after a mean follow-up of 7 months (range, 4–
16), and ﬁve have continued to receive treatment without
relapse. Although four patients kept positive cultures, the
remaining 11 patients receiving treatment were doing well at
the time of data censure. Of the 11 patients, body tempera-
ture returned to normal in seven febrile patients, nine pre-
sented improvement in cough and sputum production, and
four showed weight gain. The chest radiograph presented
slight improvement in eight patients, and three showed cavity
closure. One patient had pulmonary surgical intervention for
TB at the same time clofazimine was added to the regimen.
Adverse events
Of the 39 patients, 34 had adverse events after starting clofaz-
imine. Management including dose adjustment and medication
and incidence of adverse events is outlined in Tables 2 and 3.
Reddish black skin discolouration occurred in 31 patients,
and 16 had the clofazimine dose reduced to manage adverse
events. The remaining patients were able to continue clofazi-
mine with initial dose, with two exceptions. One patient
defaulted after 2 months of clofazimine therapy, and another
was lost after 9 months of clofazimine treatment. Ichthyosis
occurred in 11 patients, including ﬁve patients who had the
clofazimine dose reduced to manage adverse events.
TABLE 3. Incidence rate of adverse effects
Adverse event
Reporting
effect, n (%)
Any adverse event 34 (87)
Skin
Skin discolouration 31 (79)
Ichthyosis 11 (28)
Rash 2 (5)
Gastrointestinal (GI)
GI disturbance 17 (44)
Central nervous system (CNS)
Dizziness 1 (3)
Insomnia 1(3)
Depression 1(3)
Other 4 (10)
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Gastrointestinal (GI) adverse events occurred in 17
patients, including seven patients who had the clofazimine
dose reduced to manage adverse events. In nine patients, GI
events were managed by treating symptoms with antiemetic
medication. Dizziness occurred in one patient, and she took
a clofazimine dose of 100 mg once daily. Depression, a
known toxicity of clofazimine secondary to skin discolour-
ation, was seen in one patient [15]. Myelosuppression, neu-
rotoxicity or rash occurred in three patients, and they took
a linezolid dose of 1200 mg once daily.
Discussion
Patients with drug-resistant TB, compared with those with
susceptible tuberculosis, have signiﬁcantly worse outcomes.
Mitnick et al. [16] presented the most optimistic treatment
outcome results, suggesting that patients with XDR-TB trea-
ted in a community-based setting in Peru had a 60% cure rate.
The present study conﬁrmed that clofazimine might be a
valid alternative in patients with MTD-TB. Recently, Lu et al.
evaluated in vitro activity of clofazimine against 30 MDR-TB
clinical isolates. Clofazimine showed high in vitro activity
against Mycobacterium tuberculosis [8].
Despite high in vitro activity of clofazimine against clinical
strains of Mycobacterium tuberculosis, clinical experience with
clofazimine in the management of Mycobacterium tuberculosis
infections is sparse. In the present study, we have reported
on 39 patients with MDR-TB receiving clofazimine therapy.
Of the 39 patients, 15 successfully completed treatment.
Twenty-two patients achieved culture conversion. Eleven
additional patients continued to receive treatment and were
tolerating clofazimine well at data censure. These results
suggested that clofazimine contributed to favourable treat-
ment outcomes. However, it is noteworthy that treatment
success rate in our study was lower than that of Mitnick
et al. [16]. Twenty-nine patients (29/48, 60.4%) with XDR-
TB and 400 patients (400/603, 66.3%) with MDR-TB com-
pleted treatment or were cured in that report. Further-
more, four patients defaulted, and nine experienced
treatment failure with isolates remaining culture-positive. In
addition, one patient had pulmonary surgical resection at the
same time that clofazimine was added to the regimen; for
this patient, it is unknown whether sputum culture conver-
sion occurred because of the addition of clofazimine or
because of surgery.
In our series, all patients received clofazimine in combina-
tion with other drugs. Many of these antimycobacterial
agents had been used in previous regimens without microbi-
ological success. These data supported the idea of the activ-
ity of clofazimine against these MDR-TB strains, taking into
account the poor activity of the other antituberculous
agents. However, 37 patients received quinolones. Several
papers have recognized the role of quinolones in MDR-TB
[17,18]. Three patients’ treatment regimens included linezo-
lid. Several case series have evaluated the favourable efﬁcacy
of linezolid against MDR-TB.
Almost no serious side-effects and toxicities were limiting
factors for clofazimne use in our cohort. It was important to
note that we used a total daily dose of clofazimine (100 mg)
for gram-positive organisms at the time of MDR-TB treat-
ment initiation, which was used in other MDR-TB case ser-
ies, which may have decreased their risk of adverse events.
We also noted that patients in our cohort had low rates of
co-morbidities that may have no inﬂuence on their risk of
adverse events. We found that the treating clinician’s judge-
ment indicated that linezolid was most likely to be the cause
of adverse events in three patients who had myelosuppres-
sion, neurotoxicity or rash. However, myelosuppression,
neuropathy and rash resolved with dose adjustment, tempo-
rary suspension, symptom management, or close monitoring
of these patients.
The optimal dose of clofazimine that maximizes efﬁcacy
while minimizing toxicity remains to be deﬁned. Although 16
patients adjusted the dose of clofazimine due to skin discol-
ouration, our ﬁndings suggested that clofazimine at a dosage
of 100 mg once daily was well tolerated and appeared to be
an effective adjunctive medication in a treatment regimen tai-
lored to susceptibility results for patients with MDR-TB with
few other alternative treatment strategies. Although 22
patients receiving clofazimine sterilized respiratory samples
after therapy in our cohort, duration of therapy is not yet
deﬁned in patients with TB who receive clofazimine. Further,
the need for a prolonged intake of antituberculous drugs is
not related to the clinical and microbiological response but
to the long-term sterilizing activity against the sporadically
multiplying mycobacteria in caseous lesions. More clinical tri-
als are necessary to determine the optimal dose and dura-
tion of clofazimine for the treatment of MDR-TB.
There are several limitations to our study. First, our study
conclusions are limited by the small number of patients and
the retrospective nature of our analysis. Second, although
the review of medical records spanned the entire length of
MDR-TB treatment, it was limited to the time period of clof-
azimine administration. Third, the decision to initiate clofazi-
mine treatment was mainly made by a chief physician before
consultation; therefore, there were not uniform criteria for
use of the drug. Fourth, all clinical isolates in our study did
not perform DST for clofazimine, so it is hard to analyse the
correlation between treatment outcomes and clofazimine
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resistance. Despite these limitations, our study adds impor-
tant knowledge on the subject of clofazimine for the treat-
ment of MDR-TB.
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